SLU-PP-332 / BAM-15.
A combination experimental metabolic protocol for select research-protocol settings.
100 mcg / 15 mg · oral capsulePricing is shown after your free assessment, before you commit.
Free to start. No card required.
Reviewed by Lumora clinical team (Licensed provider network)Mixed evidenceSource: Client-approved product catalog; provider review required
Evidence, regulatory status, and fit vary by medication, formulation, route, and individual history.
Is this for you?
This is for you if
- Adults under specialist supervision with full informed consent
- Patients who have exhausted conventional options
- Patients with appropriate baseline labs and ongoing monitoring
This isn't for you if
Highly investigational. Mitochondrial uncouplers carry historical safety concerns. Both compounds have essentially no large-scale human clinical trial data. Not FDA-approved. Specialist supervision and informed consent are required.
SLU-PP-332 / BAM-15
This combination pairs SLU-PP-332, an estrogen-related-receptor agonist studied as an 'exercise mimetic,' with BAM-15, a mitochondrial uncoupler studied in preclinical metabolic models. Both compounds remain highly investigational and human safety data are extremely limited.
Mechanism and fit.
SLU-PP-332 activates ERR pathways that mimic the cellular adaptations produced by exercise — supporting fat oxidation, endurance, and lean muscle tone. BAM-15 acts on mitochondria to dissipate energy as heat rather than store it, potentially increasing metabolic rate. The two represent a dual-mechanism approach to fat metabolism that is studied only in carefully selected protocols.
Who this is typically for.
- Adults under specialist supervision with full informed consent
- Patients who have exhausted conventional options
- Patients with appropriate baseline labs and ongoing monitoring
What patients
most often ask.
Why is this so cautiously prescribed?
Mitochondrial uncouplers as a drug class have a complicated safety history, and neither compound has substantial human clinical data. This combination is offered only when a specialist determines it is appropriate and the patient consents with full understanding of the risks.
Who this is typically for.
These are common fit patterns from the approved catalog. Your provider determines whether treatment is appropriate.
- <ul><li>Adults under specialist supervision with full informed consent</li><li>Patients who have exhausted conventional options</li><li>Patients with appropriate baseline labs and ongoing monitoring</li></ul>
How this option
is evaluated.
The plan is provider-determined after reviewing your assessment and safety factors.
- DosingProvider-directed oral capsule.
- Typical durationShort, specialist-supervised cycles only.
- Safety and eligibilityYour provider reviews contraindications, medication interactions, goals, and safety factors before prescribing.
- A licensed provider reviews your assessment before any treatment is recommended.
- You see full pricing - visit fees, medication, labs, follow-up - before you commit.
- Your plan can be adjusted, paused, or stopped based on response and safety. Your clinician is reachable - not a chatbot.
- Compounded medications are not FDA-approved and are dispensed only when prescribed by a licensed provider.
Start with
provider review.
If you are considering SLU-PP-332 / BAM-15, the first step is a free assessment. A provider determines whether it fits your goals and medical history.
A provider determines whether treatment is clinically appropriate.